• Women's Health Research
Research Article

The Efficacy of Oral Administration of Resveratrol in Association with Feverfew (Revifastdol®) For the Treatment of Primary Dysmenorrhea: A Retrospective Cohort Study

Women’s Health Research [2018; 2(1): 1-13]
Received: 06 September 2018, Accepted: 20 September 2017, Published: 26 January 2018

Objective: To evaluate the efficacy of oral administration of resveratrol in association with feverfew (RevifastDol®, S&R Farmaceutici S.p.A., Italy) in the treatment of primary dysmenorrhea.

Methods: This study was based on a retrospective analysis of a prospectively collected database including 30 women of reproductive age suffering primary dysmenorrhea. Patients received RevifastDol® (two tablets per day for 6 months) starting three days before the beginning of the menstrual cycle and each day during the menstrual period. The intensity of dysmenorrhea was assessed by using a 10-cm visual analogue scale. The short-form health survey (SF-36) was used to investigate the quality of life.

Results: At 6-month follow up, 73.3% of the patients were either satisfied or very satisfied with the treatment. Since the first month and during all the study period, there was a significant amelioration in the intensity of dysmenorrhea compared with baseline (p < 0.05). At 6-month follow-up there was a significant reduction in the number of analgesic pills taken each day during the menstrual period and quality of life significantly improved. 

Recommended Articles

Our articles most useful